摘要
目的观察二甲双胍治疗新诊断2型糖尿病伴非酒精性脂肪肝的治疗效果。方法对2005年7月～2006年4月于我院确诊的40例新诊断2型糖尿病伴非酒精性脂肪肝患者给予二甲双胍治疗6个月,观察治疗前后肝酶学、腰围、血压、血脂、血糖、胰岛素以及HOMA胰岛素抵抗指数的变化。结果治疗后肝酶学指标下降具有统计学差异,体重指数从(26.4±3.5)至(24.2±3.3)(P<0.05),腰围在观察期间下降(幅度4cm),血糖、HOMA胰岛素抵抗指数及甘油三酯等观察指标亦有明显下降(P<0.05)。结论二甲双胍治疗新诊断2型糖尿病伴非酒精性脂肪肝,在血糖下降的同时,可明显改善肝酶学的异常和胰岛素抵抗,值得临床推广应用。
Objective To investigate the effect of mefformin on liver enzyme abnormalities in newly-diagnosed type 2 diabetes mellitus with non-alcoholic fatty liver disease. Methods The patients of newly-diagnosed type 2 diabetes mellitus with NAFLD（40 cases） were offered the mefformin for 6 months. The changes of liver enzyme tests,waist circumference,blood pressure,lipid profiles,plasma glucose,insulin and the HOMA insulin resistance index were analyzed. Results The liver enzyme declined after 6 months treatment（P〈 0.05）. Fasting and 2 hours plasma glucose,insulin lever and fasting triglycerides decreased after treatment（P 〈 0.05 ）, HOMA insulin resistance index declined from（4.8 ± 0.6 ）to（ 3.8 ± 0.4 ） （ P 〈 0.05 ） after 6 months treatment. Conclusion Mefformin improves the abnormalities of liver enzyme tests,lipid profiles, plasma glucose,insulin and the HOMA insulin resistance index etc in newly-diagnosed type 2 diabetes mellitus with NAFLD,it is worth applying in clinic.
出处
《中国现代医生》
2008年第15期19-20,共2页
China Modern Doctor
关键词
新诊断2型糖尿病
非酒精性脂肪肝
二甲双胍
胰岛素抵抗
口服降糖药
Newly-diagnosed type 2 diabetes mellitus
Non-alcoholic fatty liver disease
Metformin
Insulin resistance
Oral hypoglycemic agents
